3 results
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
Primary Objective:The primary objectives of the study are to demonstrate:• Superiority of LAS41008 versus placebo based on the proportion of subjects achievingPASI 75 at week 16 (a 75% reduction in the Psoriasis Area and Severity Index, PASI,…
The main objective:- To assess the PD properties of a single subcutaneous injection of RUC-4 in STEMI patients presenting to the CCL with the aim to perform primarycoronary angioplasty.- To assess the PK properties of a single subcutaneous injection…